Woodline Partners LP Makes New Investment in Pharvaris (NASDAQ:PHVS)

Woodline Partners LP bought a new position in shares of Pharvaris (NASDAQ:PHVS) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 44,514 shares of the company’s stock, valued at approximately $853,000. Woodline Partners LP owned 0.09% of Pharvaris at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in PHVS. JPMorgan Chase & Co. lifted its holdings in shares of Pharvaris by 1,125.3% during the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock worth $59,000 after acquiring an additional 2,847 shares during the period. Cubist Systematic Strategies LLC purchased a new position in shares of Pharvaris during the 4th quarter worth about $64,000. KLP Kapitalforvaltning AS purchased a new position in shares of Pharvaris during the 4th quarter worth about $111,000. Point72 Asset Management L.P. purchased a new position in Pharvaris during the fourth quarter worth approximately $152,000. Finally, Legal & General Group Plc raised its stake in Pharvaris by 11.2% during the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company’s stock worth $189,000 after purchasing an additional 994 shares during the period.

Pharvaris Stock Performance

NASDAQ PHVS opened at $15.99 on Tuesday. Pharvaris has a one year low of $11.51 and a one year high of $25.50. The company’s 50 day moving average price is $15.39 and its 200 day moving average price is $17.28. The firm has a market capitalization of $836.12 million, a price-to-earnings ratio of -5.71 and a beta of -2.85.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.09). Sell-side analysts forecast that Pharvaris will post -2.71 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on PHVS. JMP Securities increased their price target on shares of Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, January 31st. Cantor Fitzgerald cut their target price on Pharvaris from $28.00 to $25.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 14th.

Pharvaris Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.